Overview

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Status:
RECRUITING

Trial end date:
2031-03-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Phase:

PHASE3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

deucravacitinib